ConductScience.org, home
TO ASSESS THE EFFICACY AND SAFETY OF PF-06650833, PF-06651600, AND TOFACITINIB ALONE AND IN COMBINATION IN PARTICIPANTS WITH ACTIVE RHEUMATOID ARTHRITIS WITH AN INADEQUATE RESPONSE TO METHOTREXATE
API referenceFor AI assistants

Trial · NCT04413617

Adverse events85

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

41 to 60 of 85

Download this page as JSON
TypeEventOrgan systemGroupAffectedAt riskEvents
seriousCoronavirus infectionInfections and infestationsTofacitinib 11mg MR1102
seriousCoronavirus infectionInfections and infestationsPF-06651600 100mg077
seriousCoronavirus infectionInfections and infestationsPF-06650833 400mg MR077
seriousCoronavirus infectionInfections and infestationsPF-06650833 400mg MR + Tofacitinib 11mg MR0103
seriousCoronavirus infectionInfections and infestationsPF-06650833 400mg MR + PF-06651600 100mg0101
seriousFemur fractureInjury, poisoning and procedural complicationsTofacitinib 11mg MR0102
seriousFemur fractureInjury, poisoning and procedural complicationsPF-06651600 100mg177
seriousFemur fractureInjury, poisoning and procedural complicationsPF-06650833 400mg MR077
seriousFemur fractureInjury, poisoning and procedural complicationsPF-06650833 400mg MR + Tofacitinib 11mg MR0103
seriousFemur fractureInjury, poisoning and procedural complicationsPF-06650833 400mg MR + PF-06651600 100mg0101
seriousDiabetic ketoacidosisMetabolism and nutrition disordersTofacitinib 11mg MR0102
seriousDiabetic ketoacidosisMetabolism and nutrition disordersPF-06651600 100mg177
seriousDiabetic ketoacidosisMetabolism and nutrition disordersPF-06650833 400mg MR077
seriousDiabetic ketoacidosisMetabolism and nutrition disordersPF-06650833 400mg MR + Tofacitinib 11mg MR0103
seriousDiabetic ketoacidosisMetabolism and nutrition disordersPF-06650833 400mg MR + PF-06651600 100mg0101
seriousLumbar spinal stenosisMusculoskeletal and connective tissue disordersTofacitinib 11mg MR0102
seriousLumbar spinal stenosisMusculoskeletal and connective tissue disordersPF-06651600 100mg077
seriousLumbar spinal stenosisMusculoskeletal and connective tissue disordersPF-06650833 400mg MR177
seriousLumbar spinal stenosisMusculoskeletal and connective tissue disordersPF-06650833 400mg MR + Tofacitinib 11mg MR0103
seriousLumbar spinal stenosisMusculoskeletal and connective tissue disordersPF-06650833 400mg MR + PF-06651600 100mg0101

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Previous pageNext page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT04413617/events?page=3

API referenceFor AI assistants